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2(3H)-Furanones are a type of five-membered heterocyclic compounds of synthetic
and biological importance. The importance of this type is due to the facile opening of the
lactone ring to give acyclic products, which undergo ring closure to give other syntheti-
cally and biologically important heterocyclic compounds (1, 2). The chemistry of pyra-
zole-containing compounds is particularly interesting for antiviral (1), anti-angiogenic
activity (3), and as apoptosis-inducing agents (4), potent peroxisome proliferator-activa-
ted receptor gamma [PPARg] partial agonists (5) and antibiotics (6). Moreover, pyrida-
zinones have promising biological activities as antiplatelet (7), antihypertensive agents
(8). Biochemical studies revealed that oxadiazole caused activation on glutamic oxalo-
593
Acta Pharm. 62 (2012) 593–606 Short communication
DOI: 10.2478/v10007-012-0037-7
Heterocyclic compounds based on 3-(4-bromophenyl)






ABD EL-GALIL E. AMR3,4
1 Department of Photochemistry
National Research Centre, Cairo, Egypt
2 Virology Laboratory, Environmental
Research Division, National Research
Center, Cairo, Egypt
3 Drug Exploration & Development Chair
(DEDC), College of Pharmacy, King Saud
University, Riyadh 11451, Saudi Arabia
4 Applied Organic Chemistry Department
National Research Center, Dokki 12622
Cairo, Egypt
Accepted September 10, 2012
3-[2-(4-Bromphenyl)hydrazono]-5-phenyl-furan-2(3H)-one
(1) was used for preparation of some novel pyrazole, py-
ridazinone, oxadiazole, triazole, thiazolidine and thioxo-
pyrimidine derivatives. Some of the prepared products
were tested for anti-avian influenza virus activity and
revealed promising antiviral activity against H5N1 virus
[A/Chicken/Egypt/1/20 % (H5N1)] by determination
of both EC50 and LD50 and confirmed by plaque reduc-
tion assay on Madin-Darby canine kidney cells. Com-
pounds 3-[2-(4-bromophenyl)hydrazono]-5-phenylfuran-
-2(3H)-one (1), 1-(4-bromophenyl)-N-hydroxy-5-phenyl-
-1H-pyrazole-3-carboxamide (5) and 1-(4-bromophenyl)-
-N-{2,3-dihydro-4-hydroxy-3-phenyl-6-oxo-2-thioxopyrimi-
din-1(6H)-yl}-5-phenyl-1H-pyrazole-3-carboxamide (12a)
showed the highest effects. Detailed synthesis, spectro-
scopic data, and antiviral activity of the synthesized
compounds are reported.
Keywords: furanone, pyrazole, pyridazinone, oxadiazole,
triazole, anti-avian influenza virus (H5N1)
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acetic transaminase (GOT) and glutamate pyruvate transaminase (GPT) enzymes, inhi-
bition of gamma-glutamyl transpeptidase (g-GT) enzyme activity (9) and potent inhibi-
tion of tyrosine (10). On the other hand, substituted 1,3,4-oxadiazoles exhibit fungicidal
(11), antimicrobial and antitubercular activity (12). Simple 1,2,4-triazoles also display
some biological activities as antioxidant, urease inhibitors (13) and antiviral (14) agents.
These diverse pharmacological activities prompted us to convert furanone into other he-
terocycles bearing pyrazolyl moiety, and evaluate them for anti-viral activity. On the
other hand, influenza viruses are respiratory pathogens that affect humans and are re-
sponsible for substantial morbidity, mortality and decreased productivity worldwide
(15). Several synthetic compounds have already been utilized as potential inhibitors of
the avian virus (H5N1) and some of them demonstrated the ability to inhibit viral repli-
cation at a level comparable to the approved anti-influenza drugs zanamivir and oselta-
mivir (16).
EXPERIMENTAL
Melting points were measured using an Electrothermal 9100 digital melting point
apparatus (Büchi, Switzerland) and are uncorrected. IR spectra were recorded on a Per-
kin-Elmer 1600 FTIR (Perkin-Elmer, USA) in KBr discs. 1H NMR spectra were measured
on a Jeol 270 MHz spectrometer (Jeol, Japan) and a Bruker Avance spectrometer (300
MHz) (Bruker, Germany) in DMSO-d6, and chemical shifts were recorded in d ppm rela-
tive to the internal standard TMS. Mass spectra were run at 70 eV with a Finnigan SSQ
7000 spectrometer (Thermo electron corporation, USA) using EI; m/z values are indica-
ted in Dalton. Elemental analyses were performed on a Perkin-Elmer 2400 analyzer (Per-
kin-Elmer) and were found within ±0.4 % of the theoretical values (Table I). Follow-up
of the reactions and checking of the purity of compounds were done by TLC on silica
gel-precoted aluminum sheets (type 60 F254, Merck, Germany). All solvents and reagents
were purchased from Aldrich (Germany).
Physicochemical and spectral data for the synthesized compounds are given in Ta-
bles I and II, respectively.
Syntheses
3-[2-(4-Bromophenyl)hydrazono]-5-phenylfuran-2(3H)-one (1). – To a solution of bro-
moaniline (6.88 g, 0.04 mol) in glacial acetic acid (15 mL), conc. HCl (8 mL) was added,
then while the mixture was being cooled in ice under stirring, sodium nitrite (4.96 g,
0.068 mol) was added dropwise. To the diazonium mixture, freshly fused sodium acetate
(6.0 g) was added. Aroyl propionic acid (6.0 g, 0.04 mol) was added to acetic anhydride
(40 mL), the mixture was refluxed for 3 h, then allowed to cool at room temperature.
This solution was added dropwise, with stirring and cooling in ice, to the diazo- nium
mixture. The reaction mixture was allowed to stand overnight and the precipitate was
collected, washed with water several times and recrystallized from acetic acid to give
high yield (2).
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2-[2-(4-Bromophenyl)hydrazono]-4-oxo-4-phenylbutane hydrazide (2). – A mixture of fu-
ranone 1 (3.42 g, 0.01 mol) and hydrazine hydrate (0.64 g, 0.02 mol, 98 %) in absolute
ethanol (20 mL), was stirred at room temperature for 0.5 h. The solvent was evaporated
under vacuum and crystals were obtained.
4-[2-(4-Bromophenyl)hydrazinyl]-6-phenylpyridazin-3(2H) one (3). – A mixture of fura-
none 1 (3.42 g, 0.01 mol) and hydrazine hydrate 98 % (0.64 g, 0.02 mol) in absolute etha-
nol (25 mL) was refluxed for 2 h. The solvent was evaporated under vacuum and the
solid residue was recrystallized from benzene.
4-[2-(4-Bromophenyl)hydrazono]-1,2-dihydro-1,6-diphenylpyridazin-3(4H)-one (4). – A
mixture of furanone 1 (3.42 g, 0.01 mol) and phenylhydrazine (1.3 g, 0.012 mol) in abso-
lute ethanol (25 mL) was refluxed for 3 h. The solvent was evaporated under vacuum
and the solid residue was recrystallized from benzene/petroleum ether (60–80 °C, 1:1).
1-(4-Bromophenyl)-N-hydroxy-5-phenyl-1H-pyrazole-3-carboxamide (5). – A mixture of
furanone 1 (3.42 g, 0.01 mol), hydroxylamine hydrochloride (0.7 g, 0.01 mol) and sodium
acetate (1 g) in ethanol (25 mL) was refluxed for 4 h. The solvent was evaporated under
vacuum and the solid residue was recrystallized from benzene/petroleum ether (60–80
°C, 1:1).
5-[1-(4-Bromophenyl)-5-phenyl-1H-pyrazole-3-yl]-1,3,4-oxadiazole-2(3H)-thione (6). – A
mixture of hydrazide 2 (1.13 g, 0.003 mol), carbon disulfide (5 mL) and sodium hydrox-
ide (4 %, 3 mL) in ethanol (30 mL) was stirred at room temperature for 6 h. The solvent
was evaporated under vacuum, dissolved in hot water, and then the filtrate was neutral-
ized with diluted hydrochloric acid. The yellow precipitate was collected after washing
with water several times. The product obtained was recrystallized from benzene/petro-
leum ether (60–80 °C, 1:1).
2-{[1-(4-Bromophenyl)-5-aryl-1H-pyrazol-3-yl]carbonyl}-N-phenyl-hydrazinecarbo-thioami-
des (7a,b). – Amixture of hydrazides 2 (3.75 g, 0.01 mol) and phenyl or p-methoxyphenyl
isothiocyanate (0.01 mol) in ethanol (30 mL), was refluxed for 2 h. The mixture was
cooled, and then filtered off. The solid so obtained was recrystallized from benzene/eth-
anol (1:2.5).
1-(4-Bromophenyl)-5-phenyl-N’-(phenylcarbonyl)-1H-pyrazole-3-carbohydrazide (8). – To
a suspension of hydrazide 2 (1.13 g, 0.003 mol) in dry benzene (15 mL), benzoyl chloride
(0.42 g, 0.003 mol) was added at 25 °C and the mixture was heated under reflux at 75 °C
for 3 h. The solvent was evaporated under vacuum, and the solid residue was recrys-
tallized from benzene.
2-{1-(4-Bromophenyl)-5-phenyl-1H-pyrazole-3-yl}-5-phenyl-1,3,4-oxadiazole (9). – A mix-
ture of diaroylhydrazine 8 (0.92 g, 0.002 mol) and phosphorus oxychloride (10 mL) was
refluxed for 1 h. The mixture was cooled, poured onto crushed ice and then neutralized
with 4 % NaOH. The white precipitate was collected by filtration, washed with water
and recrystallized from benzene.
4-(4-Bromophenyl)-5-(1-aryl-5-phenyl-1H-pyrazol-3-yl)-2H-1,2,4-triazole-3(4H)-thiones
(10a,b). – A mixture of thiosemicarbazides 7a,b (0.001 mol) and NaOH (4 %, 20 mL) was
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refluxed for 2 h. The mixture was cooled, poured onto crushed ice and then neutralized
with diluted hydrochloric acid. The white precipitate was collected by filtration and
washed with water. The solid obtained was recrystallized from ethanol/water (5:1).
1-(4-Bromophenyl)-N-(4-oxo-3-arylthiazolidine-2-ylidene)-5-phenyl-1H-pyrazole-3-carbohy-
drazides (11a,b). – A mixture of thiosemicarbazide 7a or b (0.5 g, 0.001 mol), ethylchloro-
acetate (0.12 g, 0.001 mol) and NaOH pellets (0.4 g) in absolute ethanol (30 mL) was re-
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fluxed for 2 h. The solvent was evaporated under reduced pressure; the reaction mixture
was poured onto water. The obtained precipitate was filtered off, washed with water,
dried and recrystallized from ethanol.
1-(4-Bromophenyl)-N-{2,3-dihydro-4-hydroxy-3-aryl-6-oxo-2-thioxopyrimidin-1(6H)-yl}-
-5-phenyl-1H-pyrazole-3-carboxamide (12a,b). – A solution of 7a or b (0.001 mol) in sodium
ethoxide (0.023 g sodium metal in 30 mL ethanol) was heated for 30 min at 80 °C. The re-
action mixture was cooled, and then diethylmalonate (0.016 g, 0.001 mol) was poured
into water, with stirring at 70 °C for 3 h. The precipitated solid was filtered off, washed
with water, dried and recrystallized from methanol to give compounds 12a,b.
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1H NMR: 6.32 (s, 1H, =CH), 3.42 (s, 1H, NH, D2O
exchangeable), 7.80 (s, 1H, NH, D2O exchangeable),








1H NMR: 2.60–2.85 (m, 2H, –CH2), 3.42 (s, 2H, NH2,
D2O exchangeable), 7.00 (s, 1H, NHCO–, D2O







1H NMR: 5.60 (s, 1H, H pyridazinone), 6.55 (d, 2H,
J = 8Hz, Ar-H), 7.25 (d, 2H, J = 8Hz, Ar-H), 7.40
(m, 3H, Ph-H), 7.65 (m, 2H, Ph-H), 7.90 (s, 1H, NH,
pyridizinone, D2O exchangeable), 8.70 (s, 1H, NH, D2O






1H NMR: 5.9 (s, 1H, H pyridazinone), 6.35–7.4 (m,
14H, Ar-H), 8.2 (br., 1H, NHCO–, D2O exchangeable),







1H NMR: 7.00 (s, 1H, pyrazole H), 7.20–7.48 (m, 9H,
Ph-H + Ar-H), 9.20 (s, 1H, OH, D2O exchangeable),






1H NMR: 7.08 (s, 1H, pyrazole H), 7.20–7.40 (m, 9H,







1H NMR: 7.14 (s, 1H, pyrazole H), 7.30–7.66 (m, 14H,
3 Ph-H), 9.70 (br, 2H, NH, D2O exchangeable), 10.30
(s, 1H, NH, D2O exchangeable)
13C NMR: 108.31, 120.56–138.70, 143.30 (Ar-20C),







1H NMR: 3.7 (s, 3H, OCH3), 7.11 (s, 1H, pyrazole H),
7.31–7.62 (m, 13H, 3 Ph-H), 9.90 (br, 2H, NH, D2O




Virus and cells. – Avian influenza-A virus (H5N1) [isolated from cloacal swabs from
chicken, in Qalubiya governorate, Egypt, 2006 (A/chicken/Egypt/1/2006 (H5N1), ac-
cession no. FJ472343], was used to prepare low pathogenic rH5N1 by plasmid-based re-
verse genetics. The prepared H5N1 vaccine strain was used in this study to evaluate an-
tiviral activity of some synthetized compounds. Madin-Darby canine kidney (MDCK)
cells kindly provided by Dr. Richard Webby (St. Jude Children’s Research Hospital,
Memphis, TN, USA) were used for virus propagation. The MDCK cells were routinely
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1H NMR: 7.10 (s, 1H, pyrazole H), 7.20–7.90 (m, 14H
Ar-H), 10.20 (s, 1H, NH, D2O exchangeable), 10.60
(s, 1H, NH exchangeable)
13C NMR: 108.86, 121.91, 128.05–132.70, 139.02, 144.87











1H NMR: 6.70 (s, 1H, pyrazole H), 6.9–7.56 (m, 14H,






1H NMR: 3.40 (s, 3H, OCH3), 6.70 (s, 1H, pyrazole H),







1H NMR: 4.86 (s, 2H, CH2), 6.70 (s, 1H, pyrazole H),
6.90–7.66 (m, 14H, 3Ph-H), 10.60 (s, 1H, NH, D2O
exchangeable); 13C NMR: d 48.1 (CH2), 106.3 (pyrazole
C-4), 122.12–159.90 (18 Ar-C, pyrazole C-3,5 and
thiazole C-2,5), 170.36, 172.52 (2C=O)
13C NMR: 40.1 (CH2), 106.3, 116.12–142.90 (Ar-20C),






1H NMR: 3.60 (s, 1H, OCH3), 4.82 (s, 2H, CH2), 6.70
(s, 1H, pyrazole H), 6.92–7.62 (m, 13H, 3Ph-H), 10.2
(s, 1H, NH, D2O exchangeable)
13C NMR: 39.70 (CH2), 55.32 (CH3), 107.10, 114.42,
118.65, 121.37–132.29, 138.27, 144.81 (Ar-20C), 153.08,








1H NMR: 6.70 (s, 1H, pyrazole H), 6.9–7.66 (m, 14H,
3Ph-H), 14 (br,1H, NH, D2O exchangeable)
13C NMR: 39.84 (CH2), 108.69, 121.46, 127.47–132.29,
138.50, 139.34, 144.26 (Ar-20C), 145.96 (C=N), 166.65,








1H NMR: 3.4 (s, 3H, OCH3),5.4 (s, 1H, ethylene),
6.7 (s, 1H, pyrazole H), 7.1–7.66 (m, 13H, 3Ph-H),




passaged in Dulbecco’s modified Eagle medium (DMEM) containing 10 % fetal bovine
serum (FBS) and 1 % antibiotic-antimycotic mixture (penicillin-streptomycin-amphote-
ricin B).
Compound preparation for biological assays. – Prepared compounds were dissolved in
10 % dimethyl sulphoxide (DMSO) in doubly destilled water to a concentration of 10 mg
mL–1 stock solutions used for further dilutions according to the assay applied.
Cytotoxicity assay (MTT assay). – Cytotoxic activity of the extracts was tested in
MDCK cell line using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) method (17) with minor modification. Briefly, the cells were seeded in 96 well-
-plates (100 µL per well containing 3 × 105 cells mL–1) and treated with 5, 10, 20, 40, 80
and 120 µg of the sample per well. At 24 h, cells were washed with sterile phosphate
buffer (PBS) three times and the supernatant was discarded. MTT solution (20 µL of 5
mg mL–1) was added to each well and incubated at 37 °C for 4 h. Then the medium was
aspirated. In each well, the formed formazan crystals were dissolved with 200 µL of aci-
dified isopropanol (0.04 mol L–1 HCl in absolute isopropanol). Absorbance of formazan
was detected with a dual wavelength UV spectrometer at 540 nm with 620 nm reference
wavelength. The percentage of cytotoxicity compared to the untreated cells was deter-
mined. The 50 %-cytotoxicity (LD50) for each compound was calculated from standard
curve of percentage of cytotoxicity vs. sample concentration.
Antiviral activity and therapeutic index. – Antiviral activity of the compounds was de-
termined using the cytopathogenicity (CPE) assay against low pathogenic reassortant
avian influenza virus (rH5N1). Cells were seeded in 96-well cell culture plates (100 µL
per well at a density of 3 × 105 cells mL–1) and grown to confluency. Cells were then in-
fected with 100 µL of stock virus. After the virus adsorption period on cells of 2 hours at
37 °C, the virus was removed and serial dilutions (10, 20, 40 µg µL–1) of the tested com-
pounds were added, then incubated with infected cells using maintenance DMEM with
2 % FBS (100 µl per well) at 37 °C for 3 days of monitoring until complete CPE was ob-
served in the infected and untreated virus control.
Plaque reduction assay. – In a six-well cell culture plate, confluent MDCK cells were
infected with a pre-incubated mixture of 100 µL of avian influenza H5N1 virus (80–100
plaques per well) and 100 µL of DMEM [containing 2 % antibiotics and 1 mg mL–1 of
L-1-tosyl-amido-2-phenylethyl chloromethyl ketene and a different concentration of
each compound (5, 10, 20, and 40 mg mL–1)]. The plates were incubated for 1 h at 37 °C in
5 % CO2 to allow virus adsorption. After adsorption, 2 mL of agarose overlayer (2 %
agarose in DMEM 2 x containing 1 % FBS) was added to each well and mixed. The cul-
tures were incubated at 37 °C in 5 % CO2 for 3–4 days of plaque formation monitoring.
Plaques were fixed with 10 % formalin in phosphate-buffered saline for 2 h followed by
removal of the agar overlayer and staining with 0.1 % crystal violet in distilled water.
Plaques were counted manually from triplicate wells based on the plaque number but
not plaque size. Viral counts and percentage of virus reduction were calculated accord-
ing to Hayden et al. (18).
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RESULTS AND DISCUSSION
Chemistry
3-[2-(4-Bromophenyl)hydrazono]-5-phenylfuran-2(3H)-one (1) was prepared by
coupling the diazotized aniline with 5-phenyl-2(3H)-furanone according to the reported
procedures (2). Furanone 1 was reacted with hydrazine hydrate in absolute ethanol at
room temperature to give the corresponding acid hydrazide 2, which was refluxed in
ethanol to give pyridazinone derivative 3. Also, compound 3 was prepared by refluxing
compound 1 with hydrazine hydrate in absolute ethanol. The reaction of furanone 1
with phenylhydrazine was also investigated. When the reaction was carried out under
reflux conditions, pyridazinone derivative 4 was formed. Moreover, furanone 1 was re-
acted with hydroxylamine hydrochloride in ethanol under reflux to give pyrazole deri-
vative 5 (Scheme 1).
Treatment of 2 with carbon disulphide in alcoholic sodium hydroxide gave oxadia-
zolthione derivative 6. Hydrazide 2 was reacted with phenyl or p-methoxyphenyl iso-
thiocyanate to give the corresponding thiosemicarbazide derivatives 7a,b, respectively.
Also, hydrazide 2 was reacted with benzoyl chloride in dry benzene to give the corre-
sponding pyrazole derivative 8, which was treated with phosphorus oxychloride to af-
ford the corresponding 1,3,4-oxadiazole derivative 9 (Scheme 2).
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Ring closure of thiosemicarbazides 7a,b using sodium hydroxide solution, led to the
formation of the corresponding triazolthiones 10a,b. Also, the reaction of thiosemicar-
bazides 7a,b with ethyl chloroacetate in the presence of alcoholic potassium hydroxide
afforded thiazolidine derivatives 11a,b, respectively. Moreover, when thiosemicarba-
zides 7a,b were reacted with diethylmalonate in the presence of sodium ethoxide, the
corresponding thioxopyrimidin derivatives 12a,b were formed (Scheme 3).
Antiviral bioassays
Cytotoxicity assay (MTT) was carried out on all prepared compounds and accord-
ing to the results obtained, only compounds 1, 5, 7a, 8, 9, 10a, 11a, and 12a showed nota-
ble toxic effects on the biology of cells used in assays. The LD50, EC50, and therapeutic
index (TI) are presented in Fig. 1. Calculated LD50 value indicated that only 1, 5, 12a
passed the antiviral activity bioassay.
It was obvious that at concentrations of 10, 20 and 40 mg mL–1 compounds 1, 5 and
12a showed higher therapeutic indices than the other tested compounds compared to
the anti-influenza drug zanamivir. Plaque reduction assay confirmed the antiviral activ-
ity of the three compounds as shown in Fig. 2.
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Structure modifications on the lead compounds 1 and 2 afforded derivatives with a
variety of anti-avian influenza virus (H5N1) activity. For example, pyrazole-3-carboxy-
amide derivative 5 demonstrated remarkable activity due to the chromophor in the ske-
leton of this compound and displayed a significant EC50 value in regard to the parent
compound 1 (Fig. 1). However, product 2 does not appear to be advantageous in terms
of anti-avian influenza virus with respect to the parent 1 because of its open chain struc-
ture and higher hydrophilicity. Furthermore, chemical transformation/structure conver-
sion of 2 into 7 and 8 influenced positively the activity profiles against influenza virus
compared to their parent. On the contrary, a dramatic drop of activity was observed for
compound 9 because of the building of the oxazole ring. This behavior confirmed that
such functionalization hindered the interaction with the host cell receptor for virus entry
and decreased the activity. Transformation of 7a,b into 10a,b and 12a,b was accompli-
shed with significant changes in activity. Increase of activity here can be attributed to the
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triazole and pyrimidine ring formation. In particular, 10a and 12a showed remarkable
activity to the parent 7a whereas a dramatic drop of activity was noted in case of 11a
compared to 7a which was probably due to the thiazolidine ring formation. In conclu-
sion, it follows that pyrazole nucleus is essential for anti-avian influenza virus (H5N1)
activity; increased number of nitrogen atoms and amide functions sharply increases the
activity; open chains containing amide C=O conjugated with pyrazole ring are more ac-
tive than cyclized ones.
CONCLUSIONS
A series of novel pyrazole, pyridazinone, oxadiazole, triazole, thiazolidine and thio-
xopyrimidine derivatives were prepared and assayed in a variety of biological tests for
antiviral activity. Also, some of the prepared products were tested for anti-avian influ-
enza virus activity and revealed promising antiviral activity against H5N1 virus by de-
termination of both EC50 and LD50 confirmed by the plaque reduction assay on MDCK
cells. Compounds 3-[2-(4-bromophenyl)hydrazono]-5-phenylfuran-2(3H)-one (1), 1-(4-
-bromophenyl)-N-hydroxy-5-phenyl-1H-pyrazole-3-carboxamide (5) and 1-(4-bromo-
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Fig. 1. The 50 % effective concentra-
tion (EC50) and the concentration that
exhibited 50 % cytotoxicity (LD50) of
the tested compounds, compared to
the anti-influenza drug zanamivir.
Data presented at mean ± SE (n = 5).
Fig. 2. Antiviral activity of compounds
1, 5, 12a at different concentrations.
phenyl)-N-2,3-dihydro-4-hydroxy-3-phenyl-6-oxo-2-thioxopyrimidin-1(6H)-yl-5-phenyl-
-1H-pyrazole-3-carboxamide (12a) showed the highest anti-H5N1 activity of virus reduc-
tion varying from 75 % obtained by 10 mg per well to 84 % by 40 mg per well.
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S A @ E T A K
Heterocikli~ki derivati 3-(4-bromfenil) azo-5-fenil-2(3H)-furanona:
Djelovanje na virus pti~je gripe (H5N1)
EMAN M. FLEFEL, RANDA E. ABDEL-MAGEID, WALED A. TANTAWY, MOHAMED A. ALI i ABD EL-GALIL E. AMR
3-[2-(4-Bromfenil)hidrazono]-5-fenil-furan-2(3H)-on (1) upotrjebljen je za pripravu
novih derivata pirazola, piridazinona, oksadiazola, triazola, tiazolidina i tioksopirimi-
dina. Neki od sintetiziranih spojeva imaju virustatski u~inak na virus pti~je gripe H5N1.
Farmakolo{ki aktivnim spojevima odre|eni su EC50 i LD50 i dobiven je pozitivni test
redukcije plaka na MDCK stani~noj liniji. Najja~i u~inak pokazali su 3-[2-(4-bromfenil)hi-
drazono]-5-fenilfuran-2(3H)-on (1), 1-(4-bromfenil)-N-hidroksi-5-fenil-1H-pirazol-3-kar-
boksamid (5) i 1-(4-bromfenil)-N-{2,3-dihidro-4-hidroksi-3-fenil-6-okso-2-tioksopirimidin-
1(6H)-il}-5-fenil-1H-pirazol-3-karboksamid (12a).
Klju~ne rije~i: furanon, pirazol, piridazinon, oksadiazol, triazol, virus pti~je gripe (H5N1), virustatski
u~inak
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